ES2317192T3 - Derivados de benzofurano y benzotiofeno utiles para el tratamiento de la enfermedad cardiovascular. - Google Patents

Derivados de benzofurano y benzotiofeno utiles para el tratamiento de la enfermedad cardiovascular. Download PDF

Info

Publication number
ES2317192T3
ES2317192T3 ES05707417T ES05707417T ES2317192T3 ES 2317192 T3 ES2317192 T3 ES 2317192T3 ES 05707417 T ES05707417 T ES 05707417T ES 05707417 T ES05707417 T ES 05707417T ES 2317192 T3 ES2317192 T3 ES 2317192T3
Authority
ES
Spain
Prior art keywords
methyl
oxy
trifluoromethyl
benzothien
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05707417T
Other languages
English (en)
Spanish (es)
Inventor
John David GlaxoSmithKline HARLING
Paul Francis c/o GlaxoSmithKline LAMBETH
David George GlaxoSmithKline LIVERMORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2317192T3 publication Critical patent/ES2317192T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES05707417T 2004-02-12 2005-02-10 Derivados de benzofurano y benzotiofeno utiles para el tratamiento de la enfermedad cardiovascular. Expired - Lifetime ES2317192T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0403148 2004-02-12
GBGB0403148.0A GB0403148D0 (en) 2004-02-12 2004-02-12 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2317192T3 true ES2317192T3 (es) 2009-04-16

Family

ID=32011809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05707417T Expired - Lifetime ES2317192T3 (es) 2004-02-12 2005-02-10 Derivados de benzofurano y benzotiofeno utiles para el tratamiento de la enfermedad cardiovascular.

Country Status (8)

Country Link
US (1) US20070155805A1 (de)
EP (1) EP1740568B1 (de)
JP (1) JP2007522178A (de)
AT (1) ATE415395T1 (de)
DE (1) DE602005011267D1 (de)
ES (1) ES2317192T3 (de)
GB (1) GB0403148D0 (de)
WO (1) WO2005077926A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE525354T1 (de) * 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
TWI359810B (en) * 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
EP2014652B1 (de) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Aktivierungsmittel für den peroxisomproliferatoraktivierten rezeptor
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
MX2010011252A (es) * 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
US20110092517A1 (en) * 2009-08-14 2011-04-21 Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases
JP5929483B2 (ja) * 2011-05-10 2016-06-08 住友化学株式会社 植物の生長を促進する方法
JP5929482B2 (ja) 2011-05-10 2016-06-08 住友化学株式会社 植物の生長を促進する方法
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244831A1 (en) * 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
AU719663B2 (en) * 1996-12-23 2000-05-11 Merck & Co., Inc. Antidiabetic agents
KR20020070508A (ko) * 2000-01-28 2002-09-09 노보 노르디스크 에이/에스 프로피온산 유도체 및 당뇨병 및 비만의 치료에 그것의 사용
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
JP4475406B2 (ja) * 2002-07-30 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
DE60332860D1 (de) * 2002-10-28 2010-07-15 High Point Pharmaceuticals Llc Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen

Also Published As

Publication number Publication date
US20070155805A1 (en) 2007-07-05
DE602005011267D1 (de) 2009-01-08
ATE415395T1 (de) 2008-12-15
WO2005077926A3 (en) 2005-12-08
WO2005077926A2 (en) 2005-08-25
JP2007522178A (ja) 2007-08-09
EP1740568A2 (de) 2007-01-10
EP1740568B1 (de) 2008-11-26
GB0403148D0 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
ES2295601T3 (es) Acido fenilalcanoico y derivados de acido feniloxialcanoico como activadores de hppar.
ES2274914T3 (es) Derivados de tiazol para tratar trastornos relacionados con ppar.
ES2265448T3 (es) Tia- y oxazoles y sus uso como activadores de ppars.
ES2240558T3 (es) Derivados de tiazol y oxazol como activadores de receptores activados por el proliferador de peroxisoma humano.
ES2247322T3 (es) Derivados furano y tiofeno que activan receptores actiados del proliferador de peroxisonas humano activo.
US6710063B1 (en) Activators of PPAR delta
AU2002246713A1 (en) Thiazole derivatives for treating PPAR related disorders
ES2300587T3 (es) Derivados del acido feniloaxialcanoico como activadores de hppar.
US7582803B2 (en) Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP1740568B1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
EP1517882A1 (de) Amidlinker-modulatoren des peroxisom-proliferator-aktivierten rezeptors
US7105551B2 (en) Thiazole derivatives for treating PPAR related disorders
US20040132787A1 (en) 1, 2, 4-Oxadiazole derivatives as hppar alpha agonists
US20070167628A1 (en) Thiazole-2-carboxamide derivatives for use as hippar agonists in the treatment of i.a. dyslipidemia
HK1076712B (en) Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
HK1059925B (en) Thiazole derivatives for treating ppar related disorders